Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: twt who wrote (593)	11/23/1998 6:29:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 2539

twt, of course Celebrex will not be a threat to Enbrel or vice versa. Celebrex will be a threat to NSAIDs. Centocor's Remicade, if approved as a rheumatoid-arthritis treatment, would be a threat to Enbrel. MTC should be trading in a narrow trading range until it shoots up on Celebrex approval (or more exact, the advisory panel's recommendation of approval).

To: twt who wrote (593)	11/23/1998 7:29:00 PM
From: Anthony Wong	Respond to of 2539

11/23 18:00 Merck Submits New Drug Application for Vioxx(TM), An Investigational <MRK.N> Merck Submits New Drug Application for Vioxx(TM), An Investigational COX-2 Specific Inhibitor WEST POINT, Pa., Nov. 23 /PRNewswire/ -- Merck & Co., Inc. (NYSE: MRK) today announced it has submitted to the U.S. Food and Drug Administration (FDA) a New Drug Application for Vioxx(TM) (rofecoxib), an investigational once-daily, anti-inflammatory COX-2 specific inhibitor for the treatment of osteoarthritis and pain. COX-2 specific inhibitors are being studied to determine whether the apparent difference in how they work may result in fewer certain serious gastrointestinal side effects than nonsteroidal anti-inflammatory drugs, which are medications that are currently available for the treatment of osteoarthritis and pain. Merck's application includes results from 68 studies in nearly 10,000 patients that evaluated Vioxx for the treatment of the signs and symptoms of osteoarthritis and for the relief of pain. Within the next 60 days, the FDA will determine whether or not it will accept Merck's application as submitted. Merck expects to begin to file similar regulatory applications for Vioxx, worldwide, by the end of the year. Merck scientists have contributed to many important scientific discoveries in the treatment of pain and inflammation of arthritis over the past sixty years. Merck & Co., Inc. is a global research-driven pharmaceutical company that discovers, develops, manufactures and markets a broad range of human and animal health products, directly and through its joint ventures, and provides pharmaceutical benefit services through Merck-Medco Managed Care. Vioxx(TM) is the Merck trademark for rofecoxib. SOURCE Merck & Co., Inc. -0- 11/23/98 /CONTACT: Media, Kyra Lindemann, 215-652-6931, or Investor, Laura Jordan, 908-423-5185, both for Merck/ -- PHM051 -- 8859 11/23/98 17:30 EST prnewswire.com Copyright PR Newswire 1998. All rights reserved. moneynet.com@NEWS-P2&Index=1&HeadlineURL=../News/NewsHeadlines.asp&DISABLE_FORM=&NAVSVC=News\Company

To: twt who wrote (593)	11/23/1998 7:32:00 PM
From: Anthony Wong	Respond to of 2539

11/23 18:09 Merck<MRK.N> files osteoarthritis drug application WEST POINT, Pa., Nov. 23 (Reuters) - Pharmaceutical Merck & Co. Inc. said Monday it submitted a new drug application for Vioxx -- an investigational once-daily, anti-inflammatory tablet for the treatment of osteoarthritis and pain -- with the U.S. Food and Drug Administration. The company said so-called COX-2 specific inhibitors are being studied to determine whether the apparent difference in how they work may result in fewer gastrointestinal side effects than nonsteroidal anti-inflammatory drugs. Nonsteroidal anti-inflammatory drugs are drugs that are currently available for the treatment of osteoarthritis and pain, it said. The company said its application includes results from 68 studies in nearly 10,000 patients that evaluated Vioxx for the treatment of the signs and symptoms of osteoarthritis and for the relief of pain. Within 60 days, the FDA will determine whether or not it will accept Merck's application as submitted, the company said. Merck said it expects to begin to file similar regulatory applications for Vioxx worldwide by the end of the year. moneynet.com@NEWS-P2&Index=0&HeadlineURL=../News/NewsHeadlines.asp&DISABLE_FORM=&NAVSVC=News\Company